Literature DB >> 30269670

Interleukin-18 is associated with the presence of interstitial lung disease in rheumatoid arthritis: a cross-sectional study.

T Matsuo1, M Hashimoto2, I Ito3, T Kubo4, R Uozumi5, M Furu2, H Ito2, T Fujii6, M Tanaka2, C Terao7,8, H Kono9, M Mori1, M Hamaguchi10, W Yamamoto11, K Ohmura1, S Morita5, T Mimori1.   

Abstract

OBJECTIVE: Serum interleukin-18 (IL-18) levels are increased in patients with interstitial lung disease (ILD). In addition, IL-18 levels are increased in patients with rheumatoid arthritis (RA) and are associated with arthritis activity. We determined whether increased IL-18 levels are associated with ILD in RA.
METHOD: RA patients were enrolled using an RA cohort database. Plasma IL-18 levels were measured by enzyme-linked immunosorbent assay. ILD was determined by a pulmonologist and a radiologist based on chest radiography and computed tomography findings. IL-18 levels for RA with ILD and RA without ILD were compared. Associations between ILD and various markers including IL-18 and confounding factors (e.g. smoking history) were investigated by logistic regression analysis. Diagnostic values of IL-18 for the presence of ILD were investigated using receiver operating characteristics curve analysis.
RESULTS: ILD was complicated in 8.2% (n = 26) of the study population (N = 312). Plasma IL-18 levels were higher for RA patients with ILD than for RA patients without ILD (721.0 ± 481.4 vs 436.8 ± 438.9 pg/mL, p < 0.001). IL-18, Krebs von den Lungen-6, and anti-cyclic citrullinated peptide antibody titre and glucocorticoid doses were independently associated with the presence of ILD during multivariate logistic regression analysis. Sensitivity and specificity of IL-18 levels for the detection of ILD in RA patients were 65.3% and 76.3%, respectively (area under the curve = 0.73).
CONCLUSION: Plasma IL-18 levels were higher for RA patients with ILD than for those without ILD. Increased IL-18 levels were associated with the presence of ILD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30269670     DOI: 10.1080/03009742.2018.1477989

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  6 in total

1.  Advances in Disease Mechanisms and Translational Technologies: Clinicopathologic Significance of Inflammasome Activation in Autoimmune Diseases.

Authors:  J Michelle Kahlenberg; Insoo Kang
Journal:  Arthritis Rheumatol       Date:  2020-01-15       Impact factor: 10.995

Review 2.  Novel Biomarkers, Diagnostic and Therapeutic Approach in Rheumatoid Arthritis Interstitial Lung Disease-A Narrative Review.

Authors:  Alesandra Florescu; Florin Liviu Gherghina; Anca Emanuela Mușetescu; Vlad Pădureanu; Anca Roșu; Mirela Marinela Florescu; Cristina Criveanu; Lucian-Mihai Florescu; Anca Bobircă
Journal:  Biomedicines       Date:  2022-06-09

Review 3.  Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management.

Authors:  Yujie Dai; Weina Wang; Yikai Yu; Shaoxian Hu
Journal:  Clin Rheumatol       Date:  2020-08-13       Impact factor: 2.980

4.  Rheumatoid arthritis-associated interstitial lung disease: Current update on prevalence, risk factors, and pharmacologic treatment.

Authors:  Sicong Huang; Vanessa L Kronzer; Paul F Dellaripa; Kevin D Deane; Marcy B Bolster; Vivek Nagaraja; Dinesh Khanna; Tracy J Doyle; Jeffrey A Sparks
Journal:  Curr Treatm Opt Rheumatol       Date:  2020-09-01

5.  Systematic review and meta-analysis of the risk of rheumatoid arthritis-associated interstitial lung disease related to anti-cyclic citrullinated peptide (CCP) antibody.

Authors:  Hiroyuki Kamiya; Ogee Mer Panlaqui
Journal:  BMJ Open       Date:  2021-03-31       Impact factor: 2.692

Review 6.  Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis.

Authors:  Ennio G Favalli
Journal:  Rheumatol Ther       Date:  2020-07-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.